Full year 2024 Results[1]

2024 Sales

$88.8B Worldwide increased ▲ **4.3%**


Excluding the impact of translational currency: Worldwide increased ▲ **7.0%**[2,3]

Diluted earnings per share **$5.79**

Adjusted diluted earnings per share[2] **$9.98**

Earnings per share and adjusted earnings per share include $(0.67) of acquired IPR&D charges





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation. As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson."

$57.0 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 5.8%[3] or 7.5%[3] operationally[4]. Primary operational drivers:

DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL
Erleada® (apalutamide) 60 mg tablets 240 mg tablet
CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV infusion
Tremfya® (guselkumab)
Spravato™ (esketamine) CIII nasal spray
Uptravi® selexipag tablets 200-1600 mcg
Opsumit® macitentan
TECVAYLI® (teclistamab-cqyv) Injection for subcutaneous use 10 mg/mL and 90 mg/mL

$31.9 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 4.8% or 6.2% operationally[4]. Primary operational drivers:

- Electrophysiology
- Shockwave
- Abiomed
- Wound Closure
- Knees
- Contact Lenses
- Biosurgery
- Hips
- Trauma

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on January 22, 2025 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

[1] Reflects continuing operations of Johnson & Johnson
[2] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures
[3] Excluding COVID-19 Vaccine
[4] Non-GAAP measure; excludes the impact of translational currency
Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on January 22, 2025 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson&Johnson